India, July 22 -- US President Donald Trump's announcement of a tariff timeline on generic pharmaceutical imports from August 1, 2026, has put Indian drugmakers under pressure. India, a major supplier of affordable generic medicines to the US market, may face higher costs, pricing challenges, and supply-chain concerns.

The move has brought Indian pharmaceutical companies into the spotlight as they assess its impact on exports, margins, and competitiveness. Industry players may need to explore strategic changes, including local manufacturing investments and supply diversification, to navigate potential trade barriers.

Index Overview & Stock Reaction The Nifty Pharma index declined 1.90 pecrent to 25,591.8, with all 19 index constituents...